Perkins Capital Management Inc buys $3,819,627 stake in Rockwell Medical Inc (RMTI)

Rockwell Medical Inc (RMTI) : Perkins Capital Management Inc scooped up 100 additional shares in Rockwell Medical Inc during the most recent quarter end , the firm said in a disclosure report filed with the SEC on Jul 20, 2016. The investment management firm now holds a total of 478,650 shares of Rockwell Medical Inc which is valued at $3,819,627.Rockwell Medical Inc makes up approximately 4.20% of Perkins Capital Management Inc’s portfolio.

Other Hedge Funds, Including , Palo Capital added RMTI to its portfolio by purchasing 49,166 company shares during the most recent quarter which is valued at $392,345. Rockwell Medical Inc makes up approx 0.13% of Palo Capital’s portfolio.Simplex Trading reduced its stake in RMTI by selling 11,659 shares or 23.37% in the most recent quarter. The Hedge Fund company now holds 38,235 shares of RMTI which is valued at $305,115. Rockwell Medical Inc makes up approx 0.04% of Simplex Trading’s portfolio. Fox Run Management L.l.c. added RMTI to its portfolio by purchasing 31,200 company shares during the most recent quarter which is valued at $248,976. Rockwell Medical Inc makes up approx 0.12% of Fox Run Management L.l.c.’s portfolio.Cutler Group Lp boosted its stake in RMTI in the latest quarter, The investment management firm added 8,800 additional shares and now holds a total of 11,700 shares of Rockwell Medical Inc which is valued at $94,068. Rockwell Medical Inc makes up approx 0.01% of Cutler Group Lp’s portfolio. Bnp Paribas Arbitrage Sa added RMTI to its portfolio by purchasing 1,862 company shares during the most recent quarter which is valued at $15,008.

Rockwell Medical Inc opened for trading at $7.68 and hit $8.13 on the upside on Wednesday, eventually ending the session at $7.98, with a gain of 4.45% or 0.34 points. The heightened volatility saw the trading volume jump to 2,47,380 shares. Company has a market cap of $411 M.

On the company’s financial health, Rockwell Medical Inc reported $-0.10 EPS for the quarter, beating the analyst consensus estimate by $ 0.02 according to the earnings call on May 10, 2016. Analyst had a consensus of $-0.12. The company had revenue of $13.63 million for the quarter, compared to analysts expectations of $15.65 million. The company’s revenue was down -1.8 % compared to the same quarter last year.During the same quarter in the previous year, the company posted $-0.07 EPS.

Rockwell Medical Inc. (Rockwell) is a biopharmaceutical company targeting end-stage renal disease (ESRD) and chronic kidney disease (CKD) with products and services for the treatment of iron deficiency secondary hyperparathyroidism and hemodialysis. The Company’s lead branded drug Triferic is approved by the United States Food and Drug Administration (FDA). Triferic is an iron compound that is delivered to hemodialysis patients via dialysate replacing the iron loss that occurs during their dialysis treatment. Triferic enters the blood and immediately binds to transferrin and is transported to the erythroid precursor cells to be incorporated into hemoglobin. Rockwell’s generic drug Calcitriol is indicated for treating secondary hyperparathyroidism in dialysis patients. The Company manufactures sells delivers and distributes hemodialysis concentrates along with a range of ancillary products.

Comments (0)

Leave a Reply

Your email address will not be published. Required fields are marked *